Cargando…
The phosphodiesterase 4 inhibitor AA6216 suppresses activity of fibrosis-specific macrophages
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, with a poor prognosis. We previously showed the antifibrotic effects of a novel phosphodiesterase 4 (PDE4) inhibitor, AA6216. In this study, we examined the effect of...
Autores principales: | Matsuhira, Takashi, Nishiyama, Osamu, Tabata, Yuji, Kurashimo, Shinji, Sano, Hiroyuki, Iwanaga, Takashi, Tohda, Yuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408426/ https://www.ncbi.nlm.nih.gov/pubmed/34485715 http://dx.doi.org/10.1016/j.bbrep.2021.101118 |
Ejemplares similares
-
Pneumothorax in patients with idiopathic pulmonary fibrosis: a real-world experience
por: Yamazaki, Ryo, et al.
Publicado: (2021) -
Comparison of CURB-65, PSI, and qSOFA for predicting pneumonia mortality in patients with idiopathic pulmonary fibrosis
por: Yamazaki, Ryo, et al.
Publicado: (2021) -
The utility of the Japanese Association for Acute Medicine DIC scoring system for predicting survival in acute exacerbation of fibrosing idiopathic interstitial pneumonia
por: Yamazaki, Ryo, et al.
Publicado: (2019) -
Characteristics of patients with chronic idiopathic interstitial pneumonia undergoing repeated respiratory-related hospitalizations: A retrospective cohort study
por: Yamazaki, Ryo, et al.
Publicado: (2020) -
Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation
por: Yamazaki, Ryo, et al.
Publicado: (2021)